Leap Therapeutics Inc. (NASDAQ:LPTX) shares fell to a low of $2.09 before closing at $2.18. Intraday shares traded counted 0.86 million, which was -83.79% lower than its 30-day average trading volume of 470.55K. LPTX’s previous close was $2.19 while the outstanding shares total 31.63M. The firm has a beta of 1.96. The stock’s Relative Strength Index (RSI) is 46.68, with weekly volatility at 7.78% and ATR at 0.25. The LPTX stock’s 52-week price range has touched low of $0.57 and a $3.18 high. The stock traded lower over the last trading session, losing -0.46% on 06/29/20.
Investors have identified the Biotechnology company Leap Therapeutics Inc. as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around $124.43 million, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.
Leap Therapeutics Inc. (LPTX) Fundamentals that are to be considered.
When analyzing a stock, the first fundamental thing to take into account is the balance sheet. How healthy the balance sheet of a company is will determine if the company will be able to carry out all its financial and non-financial obligations and also keep the faith of its investors. For LPTX, the company has in raw cash 25.46 million on their books with 0.38 million currently as liabilities. How the trend is over time is what investors should be concerned about. The company has a healthy balance sheet as their debt profile has been on a decline. In terms of their assets, the company currently has 25984000 million total, with 9199000 million as their total liabilities.
LPTX were able to record -3.93 million as free cash flow during the third quarter of the year, this saw their quarterly net cash flow reduce by 21.57 million. In cash movements, the company had a total of -3.93 million as operating cash flow.
Potential earnings growth for Leap Therapeutics Inc. (LPTX)
What matters though is how it ends. When the core data for the company is broken down, then the stock sounds interesting. The company spent 0.38 million trying to sell their products during the last quarter, with the result yielding a gross income of 6.76 million. This allows shareholders to hold on to 31.63M with the revenue now reading -0.55 cents per share. This is a figure that is close to analyst’s prediction for their fourth quarter (-0.26 cents a share).
Having a look at the company’s valuation, the company is expected to record -1.47 total earnings per share during the next fiscal year. It is very important though to remember that the importance of trend far outweighs that of outlook. This analysis has been great and getting further updates on LPTX sounds very interesting.
Is the stock of LPTX attractive?
In related news, 10% Owner, PERCEPTIVE ADVISORS LLC bought 1,750,000 shares of the company’s stock in a transaction that recorded on Jun 22. The purchase was performed at an average price of 2.00, for a total value of 3,500,000. In the last 6 months, insiders have changed their ownership in shares of company stock by 8.60%.